Renal 1 Capsule: Veterinary Potassium Supplement
Renal 1 (marketed as Renal K+™) is a veterinary potassium supplement formulated as an oral powder for dogs and cats, not a human medication—it contains potassium gluconate (2.2 mEq per 530 mg scoop) and is specifically indicated for renal health support in potassium-deficient companion animals. 1
Product Composition and Formulation
- Active ingredient: Potassium gluconate providing 2.2 mEq of potassium per level scoop (530 mg) 1
- Formulation: Oral powder in a palatable base for veterinary use 1
- Packaging: Available in 100g containers (approximately 188 level scoops) 1
- Target species: Adult dogs and cats only 1
Intended Use and Indications
- Primary indication: Potassium supplementation in dogs and cats with potassium deficiency states 1
- Therapeutic goal: Support renal health in companion animals with chronic kidney disease 1
Critical Safety Contraindications
Absolute contraindications include 1:
- Acute, oliguric, or anuric renal failure
- Very advanced renal failure
- Adrenal insufficiency (where hyperkalemia may occur)
- Acute dehydration
- Urethral obstruction
Use with extreme caution in animals with 1:
- Cardiac disease, particularly in digitalized patients
- Any condition predisposing to hyperkalemia
Administration Guidelines
- Route: Oral administration only 1
- Timing: Administer during or after meals to reduce gastrointestinal upset 1
- Pregnancy status: Safe use in pregnant animals or those intended for breeding has not been established 1
Monitoring and Clinical Management
- Discontinuation criteria: Stop product if the animal's condition worsens or fails to improve, and consult a veterinarian 1
- Clinical vigilance: Monitor for signs of hyperkalemia, particularly in animals with cardiac disease or those receiving cardiac glycosides 1
Important Clinical Context
This is not a human pharmaceutical product—it is regulated as a veterinary supplement by the National Animal Supplement Council (NASC) 1. Healthcare providers seeking information about renal dosing adjustments for human medications should refer to established guidelines for specific drug classes, as renal impairment significantly affects pharmacokinetics and requires careful dose modifications based on creatinine clearance or estimated glomerular filtration rate 2, 3.
Human medications requiring renal dose adjustments include multiple drug classes with specific protocols: ACE inhibitors and ARBs (monitor within 1 week of initiation) 2, aminoglycosides (reduce dose/increase interval when GFR <60 mL/min/1.73 m²) 2, and many antimicrobials with varying adjustment thresholds 4, 2.